ATE357519T1 - Modifizierte und stabilizierte gdf propeptide und ihre verwendungen - Google Patents

Modifizierte und stabilizierte gdf propeptide und ihre verwendungen

Info

Publication number
ATE357519T1
ATE357519T1 AT02709366T AT02709366T ATE357519T1 AT E357519 T1 ATE357519 T1 AT E357519T1 AT 02709366 T AT02709366 T AT 02709366T AT 02709366 T AT02709366 T AT 02709366T AT E357519 T1 ATE357519 T1 AT E357519T1
Authority
AT
Austria
Prior art keywords
modified
gdf propeptides
stabilized gdf
stabilized
propeptides
Prior art date
Application number
AT02709366T
Other languages
German (de)
English (en)
Inventor
Neil M Wolfman
Soo Peang Khor
Kathleen N Tomkinson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE357519T1 publication Critical patent/ATE357519T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02709366T 2001-02-08 2002-02-08 Modifizierte und stabilizierte gdf propeptide und ihre verwendungen ATE357519T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26750901P 2001-02-08 2001-02-08

Publications (1)

Publication Number Publication Date
ATE357519T1 true ATE357519T1 (de) 2007-04-15

Family

ID=23019083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709366T ATE357519T1 (de) 2001-02-08 2002-02-08 Modifizierte und stabilizierte gdf propeptide und ihre verwendungen

Country Status (22)

Country Link
US (6) US7202210B2 (OSRAM)
EP (1) EP1397492B1 (OSRAM)
JP (3) JP4280071B2 (OSRAM)
AR (1) AR032567A1 (OSRAM)
AT (1) ATE357519T1 (OSRAM)
AU (1) AU2002243852B2 (OSRAM)
BR (1) BR0207110A (OSRAM)
CA (2) CA2674673A1 (OSRAM)
CL (1) CL2009000648A1 (OSRAM)
CY (1) CY1106629T1 (OSRAM)
DE (1) DE60219006T2 (OSRAM)
DK (1) DK1397492T3 (OSRAM)
ES (1) ES2284828T3 (OSRAM)
MX (1) MXPA03007063A (OSRAM)
NO (1) NO333427B1 (OSRAM)
NZ (2) NZ550297A (OSRAM)
PL (2) PL207202B1 (OSRAM)
PT (1) PT1397492E (OSRAM)
SG (2) SG165982A1 (OSRAM)
TW (2) TW200526779A (OSRAM)
WO (1) WO2002068650A2 (OSRAM)
ZA (2) ZA200508954B (OSRAM)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7192717B2 (en) 2002-02-21 2007-03-20 Wyeth GASP1: a follistatin domain containing protein
CA2476654A1 (en) * 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
DE60331778D1 (de) * 2002-09-16 2010-04-29 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP2314617B1 (en) 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
JP2008509927A (ja) * 2004-08-12 2008-04-03 ワイス Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8088508B2 (en) 2005-01-31 2012-01-03 Panasonic Corporation Thermal battery
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
US20060240487A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
WO2006107611A2 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
DK2032701T3 (da) * 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
ES2373246T3 (es) 2006-08-11 2012-02-01 Prosensa Technologies B.V. Oligonucleótidos monocatenarios complementarios de elementos repetitivos para el tratamiento de trastornos genéticos asociados a la inestabilidad de repeticiones de adn.
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2124999B1 (en) * 2006-12-18 2012-10-03 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for treating anemia
MX354099B (es) * 2007-02-01 2018-02-13 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
AU2008273096B2 (en) * 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
EP2167135A2 (en) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
DK2170396T3 (en) 2007-08-03 2017-03-13 Summit Therapeutics Plc PHARMACEUTICAL COMBINATIONS TO TREAT THE MUSCLE DYROPHY OF DUCHENNES
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
HUE028662T2 (en) 2007-10-26 2016-12-28 Academisch Ziekenhuis Leiden Preparations and methods for controlling muscle disorders
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
CN102088995B (zh) 2008-05-14 2016-01-20 维多利亚农业服务控股公司 血管生成素和血管生成素激动剂用于治疗疾病和障碍的用途
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
PT2340031T (pt) 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
JP2012524540A (ja) 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー．ブイ． Ｄｍｄを処置するためのイノシンを含むオリゴヌクレオチド
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
WO2011063018A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011078672A1 (en) 2009-12-24 2011-06-30 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
US20130150554A1 (en) 2010-08-20 2013-06-13 Wyeth Llc Cell culture of growth factor-free adapted cells
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
EP2691421B1 (en) 2011-03-31 2016-11-09 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
JP6400473B2 (ja) 2011-10-21 2018-10-03 ファイザー・インク 細胞培養を改善するための鉄の添加
EA201992513A1 (ru) 2012-01-09 2020-05-31 Адс Терапьютикс Са Способ лечения рака груди
CN111893117B (zh) 2012-01-27 2024-06-04 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014000042A1 (en) * 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
ES2633960T3 (es) 2012-10-15 2017-09-26 Bristol-Myers Squibb Company Procesos de cultivo de células de mamífero para la producción de proteínas
JP6401171B2 (ja) * 2012-10-24 2018-10-03 セルジーン コーポレイション 貧血の治療に使用するためのバイオマーカー
CN112957462A (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血的方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
WO2015017710A1 (en) * 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
CN104725513A (zh) * 2013-12-20 2015-06-24 中国科学院上海生命科学研究院 融合蛋白及其在治疗多发性硬化中的用途
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
FI3227675T3 (fi) 2014-12-03 2023-05-25 Celgene Corp Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
EP3949979A1 (en) 2016-01-06 2022-02-09 President and Fellows of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
TWI897070B (zh) 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
EP3897689B1 (en) 2018-12-21 2025-02-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
CA1341617C (en) 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
NZ228031A (en) 1984-07-06 1991-12-23 Sandoz Ltd Primate gm-csf and method of extraction
ATE128715T1 (de) 1984-07-16 1995-10-15 Celtrix Pharma Polypeptide induzierende faktoren in knochen und knorpel.
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5215893A (en) 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
WO1989010409A1 (en) 1988-04-08 1989-11-02 Genetics Institute, Inc. Bone and cartilage inductive compositions
US5071834A (en) 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
EP0429570B1 (en) 1989-03-28 1998-01-14 Genetics Institute, Inc. Osteoinductive compositions
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5166190A (en) 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
ATE209251T1 (de) 1990-05-16 2001-12-15 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5171579A (en) 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
EP0690873B1 (en) 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
JPH09501932A (ja) 1993-08-26 1997-02-25 ジェネティックス・インスティテュート・インコーポレイテッド ヒト・骨形態形成蛋白を用いる神経再生
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5914234A (en) 1994-07-08 1999-06-22 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-11
US5466190A (en) * 1994-07-25 1995-11-14 Deere & Company Precleaner for a cleaning shoe
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
JPH10262688A (ja) * 1994-11-30 1998-10-06 Univ Rockefeller 体重のモジュレーター、対応する核酸およびタンパク質、ならびにそれらの診断および治療用途
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6214796B1 (en) 1996-03-22 2001-04-10 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
MY120425A (en) * 1996-07-26 2005-10-31 Novartis Ag Fusion polypeptides
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2547858T3 (es) * 1997-07-14 2015-10-09 Université de Liège Doble musculación en mamíferos
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6396201B1 (en) * 1997-08-19 2002-05-28 Miyota Co., Ltd. Piezoelectric vibrator
CA2302525A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
WO1999024057A2 (en) * 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
DE69941116D1 (de) * 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
JP2002523042A (ja) 1998-08-20 2002-07-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｃｒ５、ｂｍｐ結合タンパク質、およびそれらの適用
ATE322681T1 (de) * 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
JP2003502292A (ja) * 1999-06-01 2003-01-21 バイオジェン インコーポレイテッド ヘッジホッグタンパク質のポリマー結合体及び利用
JP2003506325A (ja) 1999-07-20 2003-02-18 ファーメクサ エイ／エス Ｇｄｆ−８活性のダウン−レギュレート方法
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL350983A1 (en) * 2001-11-30 2003-06-02 Advanced Digital Broadcast Ltd Method of scanning a high-frequency signal band and apparatus therefor
US7192717B2 (en) 2002-02-21 2007-03-20 Wyeth GASP1: a follistatin domain containing protein
CA2476654A1 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
DE60331778D1 (de) 2002-09-16 2010-04-29 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2006107611A2 (en) 2005-03-23 2006-10-12 Wyeth Detection of an immune response to gdf-8 modulating agents
US20060240487A1 (en) 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents

Also Published As

Publication number Publication date
NZ527286A (en) 2006-11-30
SG165982A1 (en) 2010-11-29
US8222384B2 (en) 2012-07-17
NZ550297A (en) 2008-04-30
DE60219006T2 (de) 2007-12-13
HK1062457A1 (en) 2004-11-05
JP2009091366A (ja) 2009-04-30
PL372888A1 (en) 2005-08-08
TW200526779A (en) 2005-08-16
US8710025B2 (en) 2014-04-29
ZA200508954B (en) 2006-07-26
EP1397492A2 (en) 2004-03-17
AU2002243852B2 (en) 2007-08-16
JP2006001938A (ja) 2006-01-05
TWI329129B (en) 2010-08-21
US20100305194A1 (en) 2010-12-02
US20030104406A1 (en) 2003-06-05
US7560441B2 (en) 2009-07-14
ZA200306064B (en) 2006-02-22
PT1397492E (pt) 2007-06-15
WO2002068650A3 (en) 2003-08-21
DE60219006D1 (de) 2007-05-03
WO2002068650B1 (en) 2004-01-08
SG187989A1 (en) 2013-03-28
US20070238683A1 (en) 2007-10-11
ES2284828T3 (es) 2007-11-16
JP5013618B2 (ja) 2012-08-29
AR032567A1 (es) 2003-11-12
WO2002068650A2 (en) 2002-09-06
CL2009000648A1 (es) 2009-06-12
US20140228289A1 (en) 2014-08-14
JP4280071B2 (ja) 2009-06-17
EP1397492B1 (en) 2007-03-21
NO20033456D0 (no) 2003-08-04
PL212078B1 (pl) 2012-08-31
CA2437218A1 (en) 2002-09-06
US7737116B2 (en) 2010-06-15
CA2674673A1 (en) 2002-09-06
NO20033456L (no) 2003-10-06
MXPA03007063A (es) 2004-10-15
CY1106629T1 (el) 2012-01-25
US20070149455A1 (en) 2007-06-28
US20120252884A1 (en) 2012-10-04
NO333427B1 (no) 2013-06-03
US7202210B2 (en) 2007-04-10
BR0207110A (pt) 2005-08-16
DK1397492T3 (da) 2007-07-09
PL207202B1 (pl) 2010-11-30
JP2005507637A (ja) 2005-03-24

Similar Documents

Publication Publication Date Title
ATE357519T1 (de) Modifizierte und stabilizierte gdf propeptide und ihre verwendungen
DE60127233D1 (de) 4-aminopicolinate und ihre verwendung als herbizide
ATE533508T1 (de) Cripto-blockierende antikörper und ihre verwendung
DE50213336D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE60106599D1 (de) Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
DE50110620D1 (de) Benzoylpyrazole und ihre verwendung als herbizide
DE60326611D1 (de) N und dergleichen
FR2823558B1 (fr) Glaciere portable
DE60237872D1 (de) Knetapparat
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
ATE419248T1 (de) Phenylsubstituierte 4-hydroxy-tetrahydropyridone und ihre verwendung als schädlingsbekämpungsmittel und herbizide
DE60230162D1 (de) Polymerisate und ihre verwendung
PT1439818E (pt) Comprimido mastigavel contendo lisina
FI20011518A0 (fi) Liikeanalysaattori
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
DE60222252D1 (de) Acrylester und ihre verwendung
DE60203475D1 (de) Drosselklappe und Drossel
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
ATE347544T1 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung
ATE476164T1 (de) Saugfähiger artikel
DE60032640D1 (de) Schwefelverbindung und ihre verwendung
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen
DE60219418T8 (de) Silanylphenole und -naphthole
ATA16742001A (de) Gas-waschanlage

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397492

Country of ref document: EP